Skip to main
VCEL
VCEL logo

Vericel (VCEL) Stock Forecast & Price Target

Vericel (VCEL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vericel Corp's positive outlook is supported by anticipated growth in its MACI product, which is expected to achieve a compound annual growth rate (CAGR) in volume of approximately 14.8%, along with annual average selling price (ASP) increases of 300 to 500 basis points. The company is projected to realize a substantial revenue increase of approximately 21.2% year-over-year in FY26, driven by the conversion of biopsies to MACI and the expected expansion in market demand. Additionally, the fourth quarter is poised for a notable revenue step-up, with projected earnings of $84.8 million, representing a 26% increase quarter-over-quarter, reflecting the strengthening fundamentals of Vericel's business model.

Bears say

Vericel Corp faces a negative outlook primarily due to lowered revenue expectations for its MACI product in fiscal years 2026 and 2027, reflecting a potential decline of approximately 200 basis points. Additionally, there are significant risks associated with slower adoption rates of MACI and MACI Arthro, reduced sales in the burn care market, and challenges related to the expansion of the sales force. These factors, combined with potential misses in top-line performance, could drive the company’s stock towards historical low valuation points.

Vericel (VCEL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vericel (VCEL) Forecast

Analysts have given Vericel (VCEL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Vericel (VCEL) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $58.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $58.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vericel (VCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.